Analytical Data
-
Gene name
CIP29
- Application
-
Alternative Names
Cytokine induced protein of 29 kDa; Cytokine-induced protein of 29 kDa; HCC 1; HCC1; HSPC316; Nuclear protein Hcc 1; Nuclear protein Hcc-1; Proliferation associated cytokine inducible protein CIP29
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P82979
-
Expression Region
1-210aa
-
AA Sequence
MATETVELHKLKLAELKQECLARGLETKGIKQDLIHRLQAYLEEHAEEEANEEDVLGDETEEEETKPIELPVKEEEPPEKTVDVAAEKKVVKITSEIPQTERMQKRAERFNVPVSLESKKAARAARFGISSVPTKGLSSDNKPMVNLDKLKERAQRFGLNVSSISRKSEDDEKLKKRKERFGIVTSSAGTGTTEDTEAKKRKRAERFGIA
-
Molecular Weight
50.1 KDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CIP29 is a recombinant protein that has garnered interest in recent years due to its potential applications in various biotechnological and pharmaceutical fields. Derived from a specific genetic sequence, CIP29 has been postulated to play a significant role in cellular processes such as protein folding and stress response. The research leading to the characterization of CIP29 involved the use of advanced molecular biology techniques, including cloning, expression, and purification of the protein. Studies have indicated that CIP29 may possess unique structural and functional properties that could be harnessed in therapeutic contexts, particularly in diseases related to protein misfolding or aggregation, such as neurodegenerative disorders. Furthermore, CIP29’s stability and functionality in various conditions make it an attractive candidate for further exploration in enzyme engineering, vaccine development, and as a diagnostic tool. The ongoing investigation into its biological mechanisms and potential applications reflects the broader trend in biotechnology to innovate solutions for complex health issues through the study of recombinant proteins. Overall, the CIP29 research trajectory illustrates the intersection of fundamental science and practical applications, underscoring the importance of understanding protein dynamics in advancing medical and industrial biotechnology.
